VJHemOnc is committed to improving our service to you

IACH Focus on Leukemia 2020 | Adding ATG to post-transplantation cyclophosphamide

VJHemOnc is committed to improving our service to you

Didier Blaise

Didier Blaise, MD, PhD, Paoli-Calmettes Institute, Marseille, France, discusses adding anti-thymocyte globulin (ATG) to post-transplantation cyclophosphamide in haploidentical stem-cell transplantation. Post-transplantation cyclophosphamide has become standard prophylaxis of GvHD. Dr Blaise discusses the possibility of adding ATG to post-transplantation cyclophosphamide to further reduce the incidence of GVHD. The results are promising, however, studies are in the early stages and cannot currently suggest an improvement. This interview took place during the 2020 Annual Meeting of the International Academy for Clinical Hematology (IACH).

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter